SCHEMBL533908

SCHEMBL533908

NCc1cc2ccccc2o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 1.00
AGXT P21549 1/20 0.63
HTR2B P41595 2/20 0.49
HTR1A P08908 1/20 0.49
FLT3 P36888 1/20 0.48
CYP19A1 P11511 1/20 0.47
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CA2 P00918 1/20 0.46
ADRA2A P08913 1/20 0.45
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
CYP2A6 P11509 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MGLL Q99685 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6942058 0.98 LOXL2 (0.96) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL140395 0.83 LOXL2 (0.71) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL14075637 0.82 LOXL2 (0.69) LOXL2AGXTHTR2BHTR1AFLT3
Iodide SCHEMBL28674174 0.82 LOXL2 (0.69) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL5776752 0.80 LOXL2 (0.67) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL6243293 0.79 LOXL2 (0.66) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL9826461 0.79 LOXL2 (0.65) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL1848814 0.78 LOXL2 (0.64) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL3026368 0.78 LOXL2 (0.64) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL2090461 0.78 LOXL2 (0.64) LOXL2AGXTHTR2BHTR1AFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3510404-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF Pharmakea, Inc. (US) 2019-07-17 EP claimed
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF PHARMAKEA, INC. 2019-06-27 US claimed
WO-2018048928-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 WO claimed
WO-2018048930-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 WO claimed
US-5792791-A FOR PREVENTION AND TREATMENT OF SEROTONERGIC NEURON-RELATED DISEASES; HYPOTENSIVE AGENTS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1998-08-11 US claimed
JP-9003068-A None JP disclosed
US-20240190872-A1 FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-06-13 US disclosed
US-20240174651-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-05-30 US disclosed
EP-4370111-A1 DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTS Universität Hamburg (DE) 2024-05-22 EP disclosed
US-20240109899-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-04 US disclosed
CN-117355303-A Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders 佛罗里达大学研究基金会公司 2024-01-05 CN disclosed
EP-4284372-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS University of Florida Research Foundation, Incorporated (US) 2023-12-06 EP disclosed
JP-H093068-A BENZISOTHIAZOYL SUBSTITUTED AMINOMETHYLCOUMARONE COMPOUND BAYER AG 1997-01-07 JP disclosed
EP-0711290-A1 METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES SANOFI (FR) 1996-05-15 EP disclosed
EP-0707007-A1 Amino(thio)ether derivatives as CNS active agents MERCK PATENT GmbH (DE) 1996-04-17 EP disclosed
CN-1114834-A antidiabetic agent OTSUKA PHARMA CO LTD (JP) 1996-01-10 CN disclosed
EP-0670831-A1 QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-09-13 EP disclosed
WO-1995009159-A1 QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-04-06 WO disclosed
WO-1994026738-A1 N'-HETEROCYCLYL-N-BENZOFURANYL UREA DERIVATIVES AND THEIR ANALOGS AS ACAT INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-24 WO disclosed
US-5134140-A Psychotropic benzofuran derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1992-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174651-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS NLN, OAT, PC LOXL2 1430/4885AGXT 101/4885HTR2B 1811/4885
US-20240109899-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS STING1, MAVS, IRF3 LOXL2 507/4885AGXT 2853/4885HTR2B 1137/4885
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF LOXL2, LOXL1, LOXL3 LOXL2 1/4885AGXT 876/4885HTR2B 2188/4885
US-20240190872-A1 FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS DBI, MGAM, MGAM2 LOXL2 3477/4885AGXT 873/4885HTR2B 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.